Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Three-Arm Study to Evaluate the Effects of 3-Week Supplementation With Single (THRIVE4U(TM) TG Lipase) and Combination Lipase (THRIVE4U(TM) Spectrum Lipases) Products on Increasing Fatty Acid Absorption in Generally Healthy Adults With Potential Exocrine Pancreatic Dysfunction

NCT07893288 is registered in ClinicalTrials.gov with Danisco as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07893288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Three-Arm Study to Evaluate the Effects of 3-Week Supplementation With Single (THRIVE4U(TM) TG Lipase) and Combination Lipase (THRIVE4U(TM) Spectrum Lipases) Products on Increasing Fatty Acid Absorption in Generally Healthy Adults With Potential Exocrine Pancreatic Dysfunction
Lead sponsor
Danisco
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

digestive symptoms, gastrointestinal symptoms, healthy, impaired pancreatic function

Arms

As registered; 3 arms.

  • THRIVE4U™ TG Lipase (TP1) ExperimentalTHRIVE4U™ TG Lipase

    Study product dosing sequences: Dose Level 1(Low) → Dose Level 2 (Medium) → Dose Level 3 (High)

  • THRIVE4U™ Spectrum Lipases (TP2) ExperimentalTHRIVE4U™ Spectrum Lipases

    Study product dosing sequences: Dose Level 1(Low) → Dose Level 2 (Medium) → Dose Level 3 (High)

  • Placebo Placebo comparatorPlacebo

    Same dose throughout

Primary endpoints

Registered primary outcome measures; 6 primary.

  • To evaluate the dose-response effect of THRIVE4U™ TG Lipase (TP1) and THRIVE4U™ Spectrum Lipases (TP2) on increasing fatty acid absorption across ascending dose levels within each TP group after a single dose Day 1 of each dose level within each TP group and controlled by baseline challenge

    Plasma concentrations EPA as assessed by the O3-SACT

  • To evaluate the dose-response effect of TP1 and TP2 on increasing fatty acid absorption across ascending dose levels within each TP group after a single dose Day 1 of each dose level within each TP group and controlled by baseline challenge

    Plasma concentrations DHA as assessed by the O3-SACT

  • To evaluate the dose-response effect of TP1 and TP2 on increasing fatty acid absorption across ascending dose levels within each TP group after a single dose Day 1 of each dose level within each TP group and controlled by baseline challenge

    Plasma concentrations total fatty acid profile as assessed by the O3-SACT

  • To evaluate the effects TP1 and TP2 on increasing fatty acid absorption at different dose levels compared to placebo after a single dose Day 1 of each dose level between TP and placebo and controlled by baseline challenge

    Plasma concentrations of EPA as assessed by the O3-SACT

  • To evaluate the effects TP1 and TP2 on increasing fatty acid absorption at different dose levels compared to placebo after a single dose Day 1 of each dose level between TP and placebo and controlled by baseline challenge

    Plasma concentrations of DHA as assessed by the O3-SACT

+1 more primary endpoint

Lead sponsor's other trials

Danisco, most recent start first.